GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Gross Margin %

Telix Pharmaceuticals (Telix Pharmaceuticals) Gross Margin % : 61.06% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Telix Pharmaceuticals's Gross Profit for the six months ended in Dec. 2023 was $113.8 Mil. Telix Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $186.3 Mil. Therefore, Telix Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 61.06%.


The historical rank and industry rank for Telix Pharmaceuticals's Gross Margin % or its related term are showing as below:

TLPPF' s Gross Margin % Range Over the Past 10 Years
Min: 27.03   Med: 56.75   Max: 62.12
Current: 62.12


During the past 9 years, the highest Gross Margin % of Telix Pharmaceuticals was 62.12%. The lowest was 27.03%. And the median was 56.75%.

TLPPF's Gross Margin % is ranked better than
52.5% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs TLPPF: 62.12

Telix Pharmaceuticals had a gross margin of 61.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Telix Pharmaceuticals was 0.00% per year.


Telix Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Telix Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Gross Margin % Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only 27.04 56.75 47.97 60.54 62.12

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.82 53.06 61.80 63.46 61.06

Competitive Comparison of Telix Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Telix Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Gross Margin % falls into.



Telix Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Telix Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=206.5 / 332.436
=(Revenue - Cost of Goods Sold) / Revenue
=(332.436 - 125.942) / 332.436
=62.12 %

Telix Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=113.8 / 186.311
=(Revenue - Cost of Goods Sold) / Revenue
=(186.311 - 72.543) / 186.311
=61.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Telix Pharmaceuticals  (OTCPK:TLPPF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Telix Pharmaceuticals had a gross margin of 61.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Telix Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.